Business Wire

ASAHI-KASEI

Share
Asahi Kasei to Build a Second Plant for Ceolus™ Microcrystalline Cellulose

Asahi Kasei's Specialty Solutions SBU will build a second plant for microcrystalline cellulose [1] (trade name Ceolus™) at its Mizushima Works in Kurashiki, Okayama, Japan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210113005028/en/

Asahi Kasei currently manufactures Ceolus™, a microcrystalline cellulose used primarily in pharmaceuticals as tablet binder [2], in Nobeoka, Miyazaki, Japan.

Besides the standard-type product PH series, Ceolus™ has a lineup of KG series that greatly enhances the compactibility of tablets, and UF series that combines compactibility and flowability. These products provide solutions to a wide range of issues in the production of tablets for pharmaceuticals and supplements.

By using the KG series, tablets can be produced stably even when the amount of tablet binder that can be added is small, such as when tablets contain a large amount of active pharmaceutical ingredient (API) or when multiple APIs are formulated in a single tablet.

The UF series realizes stable production of tablets as well as the uniformity of contained API in tablets, which depend on the excellent flowability of the product.

In recent years, demand for proprietary KG and UF series products has increased, and further growth in demand is expected in the future. To meet such growing demand, Asahi Kasei has decided to make a capital expenditure to double the production capacity and achieve a stable supply through multiple production sites. This expansion will enable Asahi Kasei to meet the needs of the pharmaceutical and supplement industries and to contribute to life and living for people around the world.

[1] Microcrystalline cellulose is a white powder made from natural pulp, mainly used as an excipient for pharmaceuticals and foods

[2] Tablet binders are additives used for the purpose of providing the shape and increasing the volume of solid tablets

Capital Expenditure

Location:

Asahi Kasei Corporation Mizushima Works

 

Kurashiki City, Okayama Prefecture, Japan

Construction schedule:

Groundbreaking in September 2021

 

Completion in Spring 2023

Investment amount:

¥13 billion ($126 million at ¥103/$)

Product:

Ceolus™ microcrystalline cellulose

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

China’s Top Baijiu Brand Moutai Showcases China's Green Progress in Manufacturing at COP3015.11.2025 17:41:00 CET | Press release

On November 10 local time, the 30th United Nations Climate Change Conference (COP30) opened in Belem, a city in northern Brazil. As one of the activities at the China Pavilion of COP30, the Side Event on Ecological Civilization and Beautiful China Practice was held simultaneously, focusing on ecological civilization, sharing China's experience, and building global consensus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114596036/en/ China Pavilion at COP30 in Belem, Brazil. Addressing the topic of green transformation in traditional industries, You Yalin, Deputy Party Secretary of Kweichow Moutai Co., Ltd., shared the company's green transformation practices and experiences from the perspective of a traditional Chinese liquor producer. “We hope that every bottle of Moutai not only delivers a feast of flavor, but also conveys the idea of harmony between humans and nature. We aim to contribute China's wisdom and Moutai's

Andersen Consulting styrker sine kompetencer inden for digital transformation med Criticalcase14.11.2025 19:44:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer gennem en samarbejdsaftale med Criticalcase, der er et europæisk firma med speciale i cloud-infrastruktur, cybersikkerhed og administrerede it-tjenester. Criticalcase blev grundlagt i 1999 og har hovedsæde i Italien og har markeret sig inden for cloud-sektoren ved at designe og vedligeholde komplekse infrastrukturer for mellemstore og store virksomheder. Gennem skræddersyede løsninger tilbyder virksomheden et omfattende udvalg af tjenester, herunder sikkerhed, overvågning døgnet rundt og systemadministration, hvilket skaber pålidelighed, optimal ydeevne og beskyttelse helt ned til operativsystemniveau. "Vores mission har altid været at guide kunder gennem komplekse teknologiske udfordringer med en strategisk og praktisk tilgang," siger Luca Nunno, der er CEO for Criticalcase. "Samarbejdet med Andersen Consulting giver os mulighed for at få vores ekspertise ud til et bredere globalt publikum og skabe værdi gennem innovation og digital ekspert

Andersen Consulting samarbejder med TruScore14.11.2025 16:15:00 CET | Pressemeddelelse

Andersen Consulting annoncerer en samarbejdsaftale med TruScore, som styrker virksomhedens kompetencer inden for humankapital og hjælper kunder med at opbygge stærkere ledelsesteams og organisatoriske kulturer. Truscore, der har hovedsæde i USA, specialiserer sig i at levere fuldt skræddersyede survey-hosting-løsninger, der gør det muligt for organisationer at gennemføre whitelabel-vurderingsordninger, der er skalerbare, sikre og tilpasset deres specifikke behov. TruScore tilbyder avancerede 360-graders feedbackløsninger og samarbejder med Fortune 500-virksomheder, ledelsesudviklingsfirmaer og uafhængige coaches om at designe og administrere deres egne vurderingsplatforme og -oplevelser. "I nutidens dynamiske forretningsmiljø har organisationer brug for mere end blot en strategi – de har brug for stærk og robust ledelse for at kunne omsætte strategien til succes," siger Derek Murphy, CEO for TruScore. "Gennem dette samarbejde med Andersen Consulting kan vi få vores ekspertise inden for

SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 13:47:00 CET | Press release

-- Advancing Its Overseas Growth Strategy to Expand Japanese-Quality Aesthetic Medicine Across Asia Following Singapore -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in

SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 13:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye